518 related articles for article (PubMed ID: 22858313)
1. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
[TBL] [Abstract][Full Text] [Related]
2. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
[TBL] [Abstract][Full Text] [Related]
4. Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
Nishikawa D; Hanai N; Ozawa T; Hirakawa H; Suzuki H; Nakashima T; Hasegawa Y
Auris Nasus Larynx; 2015 Apr; 42(2):150-5. PubMed ID: 25498333
[TBL] [Abstract][Full Text] [Related]
5. A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.
Soltys SG; Choi CY; Fee WE; Pinto HA; Le QT
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):994-9. PubMed ID: 22137026
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
8. Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?
Da Mosto MC; Lupato V; Romeo S; Spinato G; Addonisio G; Baggio V; Gava A; Boscolo-Rizzo P
Ann Surg Oncol; 2013 Jan; 20(1):250-6. PubMed ID: 22836557
[TBL] [Abstract][Full Text] [Related]
9. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
[TBL] [Abstract][Full Text] [Related]
11. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
13. The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
Clavel S; Charron MP; Bélair M; Delouya G; Fortin B; Després P; Soulières D; Filion E; Guertin L; Nguyen-Tan PF
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):567-73. PubMed ID: 21310545
[TBL] [Abstract][Full Text] [Related]
14. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Tishler RB; Posner MR; Norris CM; Mahadevan A; Sullivan C; Goguen L; Wirth LJ; Costello R; Case M; Stowell S; Sammartino D; Busse PM; Haddad RI
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1036-44. PubMed ID: 16682134
[TBL] [Abstract][Full Text] [Related]
15. Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies.
Wanebo HJ; Rathore R; Chougule P; DiSiena MR; Koness RJ; McRae RG; Nigri PT; Radie-Keane K; Ready N
Ann Surg Oncol; 2011 Nov; 18(12):3479-85. PubMed ID: 21553142
[TBL] [Abstract][Full Text] [Related]
16. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
17. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Tao Y; Aupérin A; Graff P; Lapeyre M; Grégoire V; Maingon P; Geoffrois L; Verrelle P; Calais G; Gery B; Martin L; Alfonsi M; Deprez P; Bardet E; Pignon T; Rives M; Sire C; Bourhis J
Oral Oncol; 2017 Aug; 71():61-66. PubMed ID: 28688693
[TBL] [Abstract][Full Text] [Related]
18. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
[TBL] [Abstract][Full Text] [Related]
19. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
20. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
Porceddu SV; Campbell B; Rischin D; Corry J; Weih L; Guerrieri M; Grossi M; Peters LJ
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):365-73. PubMed ID: 15380568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
